Molybdenum

Molybdenum

Identity and Chemical Characterization

Molybdenum (chemical symbol: Mo; atomic number 42) is a transition metal classified as an essential trace element in human nutrition. Molybdenum is an essential trace element required by the human body for daily function. It was discovered in 1778 by Swedish chemist Karl Scheele in a mineral known as molybdenite, which was mistakenly believed to be a lead compound. Molybdenum was discovered in 1778 by the Swedish chemist Carl Wilhelm Scheele. The substance was first mistaken as lead, and after realizing that it was a new element, he named it molybdenum after the Greek word "molybdos," which means "lead-like." It was subsequently isolated as a distinct element by Swedish chemist Peter Jacob Hjelm in 1781. Molybdenum was known to be essential for plants long before its role as a cofactor in human xanthine oxidase (XO) was discovered in 1953.

In biological systems, molybdenum does not act in its free ionic form. It has no biological activity itself, but through complex biosynthetic mechanisms, it is integrated into the molybdenum cofactor (Moco) to create the active site of its associated enzymes, allowing it to perform its function. Molybdenum has been shown to act as a cofactor for a limited number of enzymes in humans: sulfite oxidase, which is believed to be most important for health, xanthine oxidase, and aldehyde oxidase. In all mammalian molybdoenzymes, functional molybdenum is present as an organic component called molybdopterin.

Natural Sources and Distribution

Many foods contain molybdenum. The amount of molybdenum in food depends on the amount of molybdenum in the soil and in the water used for irrigation. Legumes are considered to be the richest source, followed by whole grains, nuts, and beef liver. Leafy vegetables, bananas, dairy products, and chicken also contain some amount of molybdenum. Varying but typically low amounts of molybdenum may also be found in drinking water. The molybdenum content of foods depends on the molybdenum content of soils, which can vary considerably. Variation in esophageal cancer incidence worldwide has been linked to the molybdenum content in soils and food.

Common Forms and Preparations as a Supplement

Molybdenum is available in dietary supplements containing molybdenum only, in combination with other minerals, and in multivitamin/mineral products. Amounts range from about 50 mcg to 500 mcg. Forms of molybdenum in dietary supplements include molybdenum chloride, sodium molybdate, molybdenum glycinate, and molybdenum amino acid chelate. Molybdenum in single-nutrient and multiple nutrient supplements is of various forms, including sodium molybdate, ammonium molybdate, molybdenum citrate, molybdenum chloride, and molybdenum glycinate, among others. No studies have compared the relative bioavailability of molybdenum from these different forms.

Beyond standard dietary supplements, a distinct pharmaceutical form exists: tetrathiomolybdate, a specialized molybdenum compound used in clinical investigation and treatment contexts. Tetrathiomolybdate, a thiomolybdate with four sulfur atoms, can form complexes with copper preventing its absorption and blocking the activity of copper-dependent enzymes. In humans, tetrathiomolybdate therapy has been developed for Wilson's disease, a genetic disease in which the accumulation of copper in tissues leads to liver and brain damage. Recently a new formulation, bis-choline tetrathiomolybdate (TTM), also known as ALXN1840 or WTX-101, was developed.

Traditional and Historical Use

Molybdenum as an isolated chemical element has no documented historical use in traditional medicine or ethnopharmacology in the same manner as botanical remedies. Its recognition as an element dates only to 1778, and its essentiality for humans was not established until the mid-20th century.

Molybdenum was known to be essential for plants long before its role as a cofactor in human xanthine oxidase was discovered in 1953. The trajectory of scientific understanding moved from agricultural applications—where molybdenum deficiency in soils was understood to cause plant disease—toward human nutritional science. Molybdenum-rich soils and foods have long been a feature of agricultural regions, and population-level observations about the health implications of soil molybdenum content (particularly regarding esophageal cancer risk) began to emerge in the latter half of the 20th century. Two randomized nutrition intervention trials were conducted in Linxian, an area of north central China with some of the world's highest rates of esophageal and stomach cancer and a population with a chronically low intake of several nutrients.

In the industrial and agricultural context, molybdenum's interaction with copper metabolism in ruminants was recognized earlier. Excess dietary molybdenum has been found to result in copper deficiency in grazing animals (ruminants). In the digestive tract of ruminants, the formation of compounds containing sulfur and molybdenum, known as thiomolybdates, prevents the absorption of copper and can cause fatal copper-dependent disorders. This observation eventually provided the scientific foundation for the therapeutic use of tetrathiomolybdate in humans.

Key Constituents and Active Compounds: Biochemistry and Mechanisms of Action

The Molybdenum Cofactor (Moco)

The trace element molybdenum is essential for nearly all organisms and forms the catalytic centre of a large variety of enzymes such as nitrogenase, nitrate reductases, sulphite oxidase and xanthine oxidoreductases. Nature has developed two scaffolds holding molybdenum in place, the iron–molybdenum cofactor and pterin-based molybdenum cofactors.

Molybdenum is an essential trace element and crucial for the survival of animals. Four mammalian Mo-dependent enzymes are known, all of them harboring a pterin-based molybdenum cofactor (Moco) in their active site. In these enzymes, molybdenum catalyzes oxygen transfer reactions from or to substrates using water as oxygen donor or acceptor. Molybdenum shuttles between two oxidation states, Mo(IV) and Mo(VI). Following substrate reduction or oxidation, electrons are subsequently shuttled by either inter- or intra-molecular electron transfer chains involving prosthetic groups such as heme or iron-sulfur clusters.

The Four Mammalian Molybdoenzymes

Molybdenum is an essential element in the form of the molybdenum cofactor (Moco). In humans, Moco is required for four enzymes: xanthine oxidase (XO), aldehyde oxidase, sulfite oxidase (SO), and mitochondrial amidoxime-reducing component (mARC). The enzymes are involved in the oxidation of purines to uric acid, metabolism of aromatic aldehydes and heterocyclic compounds, and in the catabolism of sulfur amino acids.

• Sulfite Oxidase (SO/SOX): Sulfite oxidase is considered, by far, the most critical enzyme for human health as it catalyzes the terminal step in oxidative cysteine catabolism, the oxidation of sulfite to sulfate. SOX is localized in the intermembrane space of mitochondria and links sulfite oxidation to the reduction of cytochrome c. Sulfite oxidase catalyses the oxidation of sulfite to sulfate, necessary for metabolism of sulfur amino acids. Sulfite oxidase deficiency or absence leads to neurological symptoms and early death.
• Xanthine Oxidase/Xanthine Dehydrogenase (XO/XDH): This metal is considered essential because it is part of a complex called molybdenum cofactor that is required for the three mammalian enzymes xanthine oxidase (XO), aldehyde oxidase (AO), and sulfite oxidase (SO). XO participates in the metabolism of purines, AO catalyzes the conversion of aldehydes to acids, and SO is involved in the metabolism of sulfur-containing amino acids. Xanthine oxidase specifically catalyzes the final two steps in purine catabolism, converting hypoxanthine to xanthine and xanthine to uric acid.
• Aldehyde Oxidase (AO): XO and AO may also participate in the inactivation of some toxic substances, inasmuch as studies suggest that molybdenum deficiency is a factor in the higher incidence of esophageal cancer in populations consuming food grown in molybdenum-poor soil.
• Mitochondrial Amidoxime-Reducing Component (mARC): The mitochondrial amidoxime-reducing component (mARC) is a recently discovered molybdenum-containing enzyme in mammalians. Upon reconstitution with the electron transport proteins, cytochrome b5 and its reductase, this molybdenum enzyme is capable of reducing N-hydroxylated compounds. Recently, mARC enzymes have received a lot of attention due to their apparent involvement in lipid metabolism and, in particular, because many genome-wide association studies have shown a common variant of human mARC1 to have a protective effect against liver disease.

Electron Transfer and Catalytic Mechanism

Molybdenum functions as an electron carrier in those enzymes that catalyze the reduction of nitrogen and nitrate. Molybdenum is an essential trace element for several enzymes important to animal and plant metabolism: mammalian xanthine oxidase/xanthine dehydrogenase, aldehyde oxidase, sulfite oxidase, formate dehydrogenase, nitrate reductase and nitrogenase. The biosynthetic pathways leading to both types of cofactor have common mechanistic aspects relating to scaffold formation, metal activation and cofactor insertion into apoenzymes, and have served as an evolutionary 'toolbox' to mediate additional cellular functions in eukaryotic metabolism.

Molybdenum and the mARC Enzyme: Drug Metabolism

mARC was initially discovered as the enzyme activating N-hydroxylated prodrugs of basic amidines but has since been shown to also reduce a variety of other N-oxygenated compounds, for example, toxic nucleobase analogs. Under certain circumstances, mARC might also be involved in reductive nitric oxide synthesis through reduction of nitrite. Mitochondrial amidoxime-reducing component (mARC) enzymes are molybdenum-containing proteins that metabolize a number of endobiotics and xenobiotics.

Absorption, Bioavailability, and Pharmacokinetics

Water-soluble molybdate is efficiently absorbed from the digestive tract. The body retention is regulated by urinary excretion. Small amounts (1 mg or less) are almost completely absorbed (90–100%). Molybdenum incorporated in food is less bioavailable than molybdenum added to food. Bioavailability of molybdenum in intrinsically labelled cress ranged from 50 to 80% and for extrinsically labelled cress from 70 to 90%. Compartmental modelling studies have reported molybdenum bioavailability to be around 76–83% from a mixed diet.

Men absorbed 90% to 94% of daily intakes of molybdenum ranging from 22 to 1,490 μg. Molybdenum absorption was most efficient at the highest levels of dietary molybdenum. The amount and percentage of molybdenum excreted in the urine increased as dietary molybdenum increased, which suggests that urinary excretion rather than regulated absorption is the major homeostatic mechanism for molybdenum.

The body retention is regulated by urinary excretion. Plasma molybdenum reflects long-term intake and 24-h urinary excretion is related to recent intake. There are no biochemical markers of molybdenum status.

Dietary Reference Values and Dosage

Recommended Dietary Allowance (RDA)

The Recommended Dietary Allowance (RDA) for adult men and women is 45 μg/day. The RDA for adult men and women 19+ years is 45 micrograms daily. People 14+ years who are pregnant or lactating require 50 micrograms daily.

The U.S. Institute of Medicine (IOM, present National Academy of Sciences, Engineering, and Medicine; NASEM) established a Recommended Dietary Allowance of 45 μg/day in adult men and women in 2001, based on a small study reporting urinary excretion in balance with intake at 22 μg/day. The basis for the EAR for molybdenum consists of two carefully controlled balance studies in a total of eight young men.

Typical Dietary Intake

The average dietary intake of molybdenum by adult men and women is 109 and 76 μg/day, respectively. Most people in the United States get enough molybdenum from the foods they eat. Cereal products are the main contributors to molybdenum dietary intake, estimated to 100–170 μg/day in Nordic studies.

Tolerable Upper Intake Level (UL)

The Tolerable Upper Intake Level (UL) is 2 mg/day, a level based on impaired reproduction and growth in animals. Given the absence of human studies, the FNB established ULs for molybdenum for healthy individuals based on levels associated with impaired reproduction and fetal development in rats and mice. A tolerable upper intake level of molybdenum has been based on reproductive toxicity in rats, but the effects have not been reproduced in more recent studies.

Supplement Dosages

Molybdenum is available in dietary supplements containing molybdenum only, in combination with other minerals, and in multivitamin/mineral products. Amounts range from about 50 mcg to 500 mcg. In the case of a documented acquired deficiency (see below), the only documented case of acquired molybdenum deficiency occurred in a patient with Crohn's disease on long-term total parenteral nutrition (TPN) without molybdenum. The patient developed rapid heart and respiratory rates, headaches, and night blindness, and ultimately became comatose. The patient was diagnosed with defects in uric acid production and sulfur amino acid metabolism. The patient's clinical condition improved and the amino acid intolerance disappeared when the TPN solution was supplemented with molybdenum in the form of ammonium molybdate (300 μg/day).

Supplementation of molybdenum to preterm infants is recommended in doses of 0.3–5 μg molybdenum/kg body weight per day if enteral, and approximately 0.25 μg molybdenum/kg body weight per day if parenteral.

Scientific Evidence by Area of Use

1. Essential Enzymatic Functions and Sulfur Amino Acid Metabolism

The strongest evidence for molybdenum's importance in human health comes from observations in individuals with genetic disorders of Moco metabolism, not from clinical trials of supplementation. Because molybdenum functions only in the form of the Moco in humans, any disturbance of Moco metabolism can disrupt the function of all molybdoenzymes. Current understanding of the essentiality of molybdenum in humans is based largely on the study of individuals with very rare inborn metabolic disorders caused by a deficiency in Moco.

Evidence strength: The role of molybdenum as a cofactor for critical mammalian enzymes is firmly established at the biochemical level. Clinical evidence of molybdenum's essentiality in health humans derives primarily from genetic disorder studies and a single documented TPN deficiency case, not controlled supplementation trials.

2. Purine Metabolism and Uric Acid Production

Xanthine oxidase, a molybdoenzyme, is directly involved in the catabolism of purines to uric acid. In humans, Moco is required for four enzymes: xanthine oxidase, aldehyde oxidase, sulfite oxidase, and mitochondrial amidoxime-reducing component (mARC). The enzymes are involved in the oxidation of purines to uric acid, metabolism of aromatic aldehydes and heterocyclic compounds, and in the catabolism of sulfur amino acids. Paradoxically, excessive molybdenum intake activates xanthine oxidase to the point of overproducing uric acid, a mechanism associated with gout-like symptoms at very high exposures (see Safety section).

Evidence strength: Biochemically well-established; no human supplementation trials have investigated the effects of molybdenum on purine metabolism at nutritional doses in healthy individuals.

3. Cancer Prevention — The Linxian, China Intervention Trials

The most extensive human evidence examining molybdenum in relation to a specific disease comes from the Linxian Nutrition Intervention Trials in China. These were prompted by the ecological observation that the molybdenum content of foods depends on the molybdenum content of soils, which can vary considerably, and variation in esophageal cancer incidence worldwide has been linked to the molybdenum content in soils and food.

Two randomized nutrition intervention trials were conducted in Linxian, an area of north central China with some of the world's highest rates of esophageal and stomach cancer and a population with a chronically low intake of several nutrients. One trial used a factorial design that allowed assessment of the effects in nearly 30,000 participants of daily supplementation with four nutrient combinations: retinol and zinc; riboflavin and niacin; vitamin C and molybdenum; and beta-carotene, alpha-tocopherol, and selenium. The second trial provided daily multiple vitamin-mineral supplementation or placebo in 3,318 persons with esophageal dysplasia, a precursor to esophageal cancer.

Finally, a compromise was made that nine nutrients were grouped into four sets (factors): (A) retinol and zinc; (B) riboflavin and niacin; (C) ascorbate and molybdenum; and (D) α-tocopherol, β-carotene, and selenium, with each nutrient at 2 to 3 times the dose of the US Recommended Daily Allowance.

The results demonstrated no benefit from the molybdenum-containing combination: No significant effects on mortality rates from all causes were found for supplementation with retinol and zinc, riboflavin and niacin, or vitamin C and molybdenum. Moreover, the 25-year follow-up of this trial found that co-supplementation with these two micronutrients actually led to small increases in risk of death from gastric cardia cancer and cancer in general, but not death from esophageal cancer.

Evidence strength: A large, well-designed randomized controlled trial and its long-term follow-up. The evidence does not support a protective role for supplemental molybdenum (combined with vitamin C) against esophageal or gastric cancer. The ecological association between low soil molybdenum and high esophageal cancer rates has not been substantively supported in intervention trials.

4. Wilson's Disease and Copper Regulation — Tetrathiomolybdate

The copper-chelating form of molybdenum, tetrathiomolybdate (TM), has been investigated as a treatment for Wilson's disease. Molybdenum has been used clinically to treat Wilson disease. In Wilson disease, copper that is not bound to ceruloplasmin circulates and accumulates in tissues, resulting in liver damage, neurological complications, and brain damage. Molybdenum as tetrathiomolybdate can form a strong complex with copper and protein. Tetrathiomolybdate given with food forms complexes with dietary copper and protein and prevents copper absorption. Tetrathiomolybdate given without food is absorbed into the bloodstream and forms complexes with circulating copper and albumin, preventing the copper from accumulating in cells and causing toxicity.

Tetrathiomolybdate (TTM) is a promising new treatment for Wilson's disease which has been demonstrated both in an animal model and in clinical trials. X-ray absorption spectroscopy suggests that TTM acts as a novel copper chelator, forming a complex with accumulated copper in liver.

Evidence strength: Preliminary to moderate. Clinical trial data exist for tetrathiomolybdate in Wilson's disease, but this is a distinct pharmaceutical application from dietary supplementation with standard molybdenum compounds.

5. Cancer — Tetrathiomolybdate as an Anti-Angiogenic Agent

More recently, tetrathiomolybdate use has been explored for the treatment of cancer and inflammatory diseases. The copper-chelating ability of tetrathiomolybdate, the form of molybdenum used to treat Wilson disease, has led to interest in its use for antitumor therapy. Copper promotes angiogenesis, and angiogenesis is an important step in the progression of cancer, because tumors need to become vascularized as they grow. Preclinical studies to date have been generally promising. Cell studies have shown that tetrathiomolybdate can reduce angiogenesis and cancer cell proliferation. Furthermore, thiomolybdate administered to dogs with various advanced tumors showed stabilization or tumor reduction in 9 of 13 of the dogs.

Evidence strength: Preclinical (in vitro and animal) only. No adequate human clinical trial data currently support the use of tetrathiomolybdate as an anticancer agent outside of investigational settings.

6. Liver Disease — The mARC1 Genetic Association

An emerging area of scientific interest concerns the relationship between mARC enzyme variants and liver disease. Many genome-wide association studies have shown a common variant of human mARC1 to have a protective effect against liver disease. While the experiments culminating in the discovery of mARC were initially motivated by its property to metabolize xenobiotics and pharmaceutical drugs in particular, recent studies showed that a mARC2 KO has dramatic effects on lipid metabolism in a murine KO model and that protein variants of human mARC1 convey a protective effect against diseases of the liver.

Evidence strength: Genetic association data and animal/cell models. This is a very early and emerging area of research. No human interventional studies using molybdenum supplementation for liver protection have been conducted.

7. Drug Metabolism

The mitochondrial amidoxime-reducing component (mARC) is a recently discovered molybdenum-containing enzyme in mammalians. Upon reconstitution with the electron transport proteins, cytochrome b5 and its reductase, this molybdenum enzyme is capable of reducing N-hydroxylated compounds. It was named mARC because the N-reduction of amidoxime structures was initially studied using this isolated mitochondrial enzyme. mARC was initially discovered as the enzyme activating N-hydroxylated prodrugs of basic amidines but has since been shown to also reduce a variety of other N-oxygenated compounds.

Evidence strength: Mechanistic and biochemical evidence is strong, but clinical implications for molybdenum nutritional status and drug metabolism have not been studied in humans.

Body Systems and Health Areas Associated with Molybdenum

• Hepatic/Metabolic: Central role of SO, XO, and AO in metabolism of amino acids, purines, and aromatic compounds; emerging evidence linking mARC1 variants to liver disease protection.
• Neurological: Sulfite oxidase catalyses the oxidation of sulfite to sulfate, necessary for metabolism of sulfur amino acids. Sulfite oxidase deficiency or absence leads to neurological symptoms and early death. Molybdenum cofactor deficiency causes severe neonatal encephalopathy.
• Renal: The kidneys are the primary regulatory organ for molybdenum homeostasis. Excess molybdenum from food is rare because the kidneys regulate levels of this mineral efficiently and remove the excess through urine.
• Purine/Uric Acid Metabolism: Via xanthine oxidase, molybdenum is integral to purine catabolism and uric acid synthesis, connecting it to conditions such as gout at extremes of intake.
• Sulfur Amino Acid Catabolism: Via sulfite oxidase, molybdenum is required for the proper metabolism of cysteine and methionine.
• Drug Metabolism: Via mARC enzymes, molybdenum participates in the reductive biotransformation of N-hydroxylated pharmaceutical compounds and endogenous molecules.
• Copper Homeostasis: At pharmacological doses as tetrathiomolybdate, molybdenum profoundly modulates copper bioavailability and is under investigation for copper-excess disorders.

Deficiency

Dietary Deficiency

There are no reports on clinical signs of dietary molybdenum deficiency in otherwise healthy humans. Molybdenum deficiency is very rare in the United States. Because molybdenum deficiency is rare, molybdenum status is not assessed in clinical settings.

The sole documented case of acquired deficiency in a human occurred in a patient on TPN. The only documented case of acquired molybdenum deficiency occurred in a patient with Crohn's disease on long-term total parenteral nutrition without molybdenum added to the TPN solution. The patient developed rapid heart and respiratory rates, headaches, and night blindness, and ultimately became comatose. The patient was diagnosed with defects in uric acid production and sulfur amino acid metabolism. The patient's clinical condition improved and the amino acid intolerance disappeared when the TPN solution was supplemented with molybdenum in the form of ammonium molybdate (300 μg/day).

Molybdenum Cofactor Deficiency (MoCD) — Genetic Disorder

Molybdenum cofactor deficiency (MoCD) includes three ultrarare autosomal recessive inborn errors of metabolism (MoCD type A, MoCD-B, and MoCD-C) that cause sulfite intoxication disorders. Mutations in the molybdenum cofactor biosynthetic pathway lead to the combined deficiency of all molybdenum-dependent enzymes. Molybdenum cofactor deficiency Type A is due to mutations in the MOCS1 gene, while Type B deficiency is caused by mutations in MOCS2.

Of the 58 MoCD patients studied, 49 had first presenting symptoms by Day 28 (neonatal onset). One-year survival rates were 77.4% (overall), 71.8% (neonatal onset MoCD-A), and 76.9% (neonatal onset MoCD-B); median ages at death were 2.4, 2.4, and 2.2 years, respectively.

Safety Considerations

General Safety from Dietary Sources

In healthy people, consumption of a diet high in molybdenum usually does not pose a health risk because the molybdenum is rapidly excreted in urine. Research is not available on molybdenum as a treatment for specific diseases or health conditions in humans.

Toxicity at High Exposures

One study assessed the effect of high dietary intakes of molybdenum (10–15 mg/day) in an area of Armenia where the soil contains very high levels of molybdenum. The affected individuals experienced achy joints, gout-like symptoms, and abnormally high blood levels of uric acid. Increased serum concentrations of uric acid and ceruloplasmin (an iron-oxidizing enzyme) have been reported in occupationally exposed workers in a molybdenite roasting plant. Gout-like symptoms have also been reported.

Although a handful of studies have associated very high intakes of molybdenum with elevated uric acid levels, copper deficiency, and infertility, subsequent research has not confirmed these findings, with negative effects seen more commonly in animal research than humans.

Acute molybdenum toxicity is rare, but it can occur with industrial mining and metalworking exposure. Chronic use of high-dose supplements or occupational exposure, such as in miners and metalworkers exposed to high levels of molybdenum in air and soil, may lead to toxicity.

Basis and Limitations of the Upper Intake Level

Given the absence of human studies, the FNB established ULs for molybdenum for healthy individuals based on levels associated with impaired reproduction and fetal development in rats and mice. A tolerable upper intake level of molybdenum has been based on reproductive toxicity in rats, but the effects have not been reproduced in more recent studies. Little data are available on molybdenum toxicity in humans.

Copper Interaction

Tetrathiomolybdate (TM) is a molecule that can form high-affinity complexes with copper, controlling free copper (copper that is not bound to ceruloplasmin), and inhibiting copper chaperones and copper-containing enzymes. TM's ability to lower free copper levels is exploited in the treatment of Wilson's disease, a genetic disorder characterized by copper accumulation in tissues. At very high dietary intakes (as seen in occupationally exposed populations or in ruminants), secondary copper deficiency can theoretically occur via a related thiomolybdate mechanism, though this has not been reliably demonstrated in humans at supplemental doses within the UL.

Drug Interactions

Molybdenum has no known, clinically relevant, interactions with medications. Molybdenum is not known to interact or interfere with any medicines.

Basis for UL Values (Summary)

The daily upper limits for molybdenum include intakes from all sources—food, beverages, and supplements—and are listed in micrograms (mcg). For adults (including pregnant and lactating women), the UL for molybdenum for adults 19+ years and those pregnant and lactating is 2,000 micrograms daily.

Summary of Evidence Strength

Research is not available on molybdenum as a treatment for specific diseases or health conditions in humans. The biochemical and enzymatic roles of molybdenum are thoroughly characterized, and the evidence for its essentiality as a cofactor in four critical mammalian enzymes is robust. However, the evidence base for using supplemental molybdenum (beyond correcting documented deficiency) to prevent or treat disease is either absent or, in the case of cancer prevention, negative from large randomized trials. Tetrathiomolybdate, as a pharmaceutical-grade copper-depleting agent, represents a distinct area of clinical investigation with emerging human trial data, but is not equivalent to standard dietary supplement use.

References

• NIH Office of Dietary Supplements — Molybdenum Health Professional Fact Sheet
• NIH Office of Dietary Supplements — Molybdenum Consumer Fact Sheet
• National Academies of Sciences — Dietary Reference Intakes: Molybdenum (NCBI Bookshelf)
• Oskarsson A, Kippler M. Molybdenum — a scoping review for Nordic Nutrition Recommendations 2023. Food & Nutrition Research, 2023. PMC10770642
• Schwarz G, Belaidi AA. Molybdenum in human health and disease. Met Ions Life Sci. 2013;13:415–50. PubMed 24470099
• Schwarz G, Mendel RR, Ribbe MW. Molybdenum cofactors, enzymes and pathways. Nature. 2009;460(7257):839–47. PubMed 19675644
• Linus Pauling Institute Micronutrient Information Center — Molybdenum
• Harvard T.H. Chan School of Public Health — The Nutrition Source: Molybdenum
• Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China. J Natl Cancer Inst. 1993;85(18):1483–92. PubMed 8360931
• Qiao YL, et al. The Linxian trials: mortality rates by vitamin-mineral intervention group. J Natl Cancer Inst. 1995. PubMed 7495242
• Misko AL, et al. Molybdenum cofactor deficiency: A natural history. J Inherit Metab Dis. 2022. PMC9313850
• Ott G, Havemeyer A, Clement B. The fourth mammalian molybdenum enzyme mARC: current state of research. J Biol Chem. 2011. PubMed 21942410
• Struwe MA, Scheidig AJ, Clement B. The mitochondrial amidoxime reducing component — from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target. J Biol Chem. 2023. PMC10637980
• Molybdenum. In: Present Knowledge in Nutrition. ScienceDirect. 2020.
• Sardesai VM. Molybdenum: An Essential Trace Element. Nutrition in Clinical Practice. 1993;8(6):277–281.